Pfizer Corp v Commissioner of Patents (No 2)

Link copied
Case Copied 29 min read

FEDERAL COURT OF AUSTRALIA

Pfizer Corp v Commissioner of Patents (No 2) [2006] FCA 1176

PATENTS – date for calculation of extension of term of patents relating to pharmaceutical substances – “first inclusion in the Australian Register of Therapeutic Goods” not limited to regulatory approval to market pharmaceutical substance in Australia – correct date if no “pre-TGA marketing approval” granted is first entry in the Australian Register of Therapeutic Goods, including an entry as listed goods for export only

STATUTORY CONSTRUCTION – extrinsic materials relevant to context and legislative history – materials equivocal on whether “first inclusion” means registration or listing – legislative objective that patentee should have “effective patent life” to exploit patent

WORDS AND PHRASES – “first inclusion in the Australian Register of Therapeutic Goods” – “first regulatory approval date” – “pre-TGA marketing approval”

Patents Act 1990 (Cth) ss 70(1), 70(3), 70(5), 70(6), 77
Patents Regulations 1991 (Cth) reg 10.7(7)
Acts Interpretation Act 1901 (Cth) s 15AB
Therapeutic Goods Act 1989 (Cth) ss 9A, 19A, 25, 26, 31(2) repealed s 17

Atlantis Corporation Pty Ltd v Schindler [1997] FCA 455 cited
Doric Products Pty Ltd v Lockwood Security Products Pty Ltd (2002) 54 IPR 495 cited
H LundbeckA/S v Commissioner of Patents (2006) 150 FCR 269 applied
Newcastle City Council v GIO General Limited (1997) 191 CLR 85 applied
Pfizer Corp v Commissioner of Patents (2006) 67 IPR 646 cited
Re Pfizer Corporation (2005) 67 IPR 201 affirmed
Stevens v Kabushiki Kaisha Sony Computer Entertainment (2005) 221 ALR 448 cited
Woolworths Limited v BP plc [2006] FCAFC 132 cited
Woolworths Limited v BP plc (2006) 150 FCR 134 cited

PFIZER CORP, PFIZER LTD, PFIZER INC AND PFIZER RESEARCH & DEVELOPMENT COMPANY N.V/SA v COMMISSIONER OF PATENTS AND SPIRIT PHARMACEUTICALS PTY LIMITED (ACN 109 225 747)

NSD 1955 OF 2005

BENNETT J
11 SEPTEMBER 2006
SYDNEY

IN THE FEDERAL COURT OF AUSTRALIA

NEW SOUTH WALES DISTRICT REGISTRY

NSD 1955 OF 2005

ON APPEAL FROM THE COMMISSIONER OF PATENTS

BETWEEN:

PFIZER CORP
First Applicant

PFIZER LTD
Second Applicant

PFIZER INC
Third Applicant

PFIZER RESEARCH & DEVELOPMENT COMPANY N.V/SA
Fourth Applicant

AND:

COMMISSIONER OF PATENTS
First Respondent

SPIRIT PHARMACEUTICALS PTY LIMITED
(ACN 109 225 747)
Second Respondent

JUDGE:

BENNETT J

DATE OF ORDER:

11 SEPTEMBER 2006

WHERE MADE:

SYDNEY

THE COURT ORDERS THAT:

1.The application, being an appeal from the Commissioner of Patents, is dismissed. 

2.The applicants pay the first respondent’s costs.

Note:    Settlement and entry of orders is dealt with in Order 36 of the Federal Court Rules.


IN THE FEDERAL COURT OF AUSTRALIA

NEW SOUTH WALES DISTRICT REGISTRY

NSD 1955 OF 2005

ON APPEAL FROM THE COMMISSIONER OF PATENTS

BETWEEN:

PFIZER CORP
First Applicant

PFIZER LTD
Second Applicant

PFIZER INC
Third Applicant

PFIZER RESEARCH & DEVELOPMENT COMPANY N.V/SA
Fourth Applicant

AND:

COMMISSIONER OF PATENTS
First Respondent

SPIRIT PHARMACEUTICALS PTY LIMITED
(ACN 109 225 747)
Second Respondent

JUDGE:

BENNETT J

DATE:

11 SEPTEMBER 2006

PLACE:

SYDNEY

REASONS FOR JUDGMENT

  1. The Patents Act 1990 (Cth) (‘the Act’) provides for the…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Pfizer Corp v Commissioner of Patents (No 2) and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2006] FCA 1176
Decision Date

CaseChat Overview and Summary

In the matter of Pfizer Corp v Commissioner of Patents (No 2), the Federal Court of Australia was called upon to determine the legal implications of exporting patented pharmaceutical products from Australia and the requisite regulatory requirements for inclusion in the Australian Register of Therapeutic Goods (ARTG). The dispute involved Pfizer Corp, which held patents for certain pharmaceutical products, and the Commissioner of Patents, with Spirit Pharmaceuticals Pty Limited joining as a respondent to provide evidence relevant to the regulatory requirements and patent exploitation. The central issue was whether the inclusion of a product in the ARTG for export purposes qualified as the "first inclusion" under the Patents Act 1990 (Cth) for calculating the extension of patent terms.

The court had to decide whether an export-only listing of a patented product in the ARTG constituted the "first inclusion" under section 70 of the Act, thereby affecting the calculation of patent term extensions under section 77. The crux of the legal issue was the interpretation of the statutory language concerning "first inclusion" and "first regulatory approval date," and whether the export-only listing of a patented product in the ARTG could be considered a form of regulatory approval that triggers the commencement of the patent term extension period. Additionally, the court needed to assess the relevance and admissibility of expert evidence from Dr Walter regarding the regulatory requirements for Listed Goods and the extent to which an export-only listing enabled patent exploitation.

The Federal Court held that an inclusion in the ARTG, including an export-only listing as Listed Goods, qualifies as the "first inclusion" for the purposes of section 70 of the Act. The court determined that this inclusion, if it precedes registration for marketing in Australia and no "pre-TGA marketing approval" was given, constitutes the "first inclusion in the ARTG" and the "first regulatory approval date" for calculating the period of extension under section 77. The court dismissed the application on the grounds that the appeal against the Commissioner's decision should not succeed. Furthermore, the court ordered that the applicants pay the costs of the Commissioner, although Spirit Pharmaceuticals, having joined the proceeding as a respondent, had agreed not to seek costs. The court reserved the matter of Pfizer’s application for a stay, its associated costs, and any undertaking regarding damages for further submissions from the parties.

Orders

Orders of the court

1. The application, being an appeal from the Commissioner of Patents, is dismissed.

2. The applicants pay the first respondent’s costs.

Background

Background to the litigation

Evidence

Evidence Before The Court

The right to exploit an invention is not limited to the sale of a patented substance in Australia. For example, to manufacture a patented substance in Australia for sale in another country is to exploit an invention within the meaning of the Act (Sch 1 of the Act).Dr Walter’s Evidence Spirit Pharmaceuticals Pty Limited is an Australian pharmaceutical company with a commercial interest in the expiry date of at least one of the Pfizer patents. Spirit was joined as a respondent to this proceeding on 1 March 2006 (Pfizer Corp v Commissioner of Patents (2006) 67 IPR 646). Spirit seeks to adduce evidence of Dr Walters, a person experienced in matters relating to the ARTG, to establish the regulatory requirements of Listed Goods and the extent to which a patentee with an export only listing can exploit a patent. The evidence is said to answer Pfizer’s contention that there is no requirement to lodge extensive data in support of an application for inclusion in the ARTG as Listed Goods, which is a requirement for goods to be Registered Goods. Spirit also wishes to respond to any suggestion that an export only listing does not allow exploitation of the patent which compensates for regulatory and product development delays. Such evidence was tendered by Pfizer before the Commissioner and was referred to in the decision. Pfizer now contends that the issue is one of statutory construction to which this evidence is not relevant. Pfizer submits that all parties now accept that there can be different inclusions in the ARTG. Pfizer accepts that it is necessary to provide data in support of an application for Listed Goods and that an export only listing enables the patentee to exploit the invention, albeit on a less than “fully effective” basis. The point that Pfizer wishes to make is that the provision of data for Registered Goods is more onerous and extensive. This itself is said to result in regulatory delay before there can be marketing in Australia and full exploitation of the patent. Pfizer relies on the distinction between the evaluation of Registered Goods and Listed Goods in ss 25 and 26 of the TG Act and stresses that it is not necessary to provide data of efficacy for an application for Listed Goods. Section 25 of the TG Act sets out the matters relevant to the evaluation of Registered Goods, which include a positive requirement that those goods are evaluated for quality, safety and efficacy (s 25(1)(d)). Section 26, which deals with matters relevant to Listed Goods, makes no express reference to efficacy and is couched in negative terms, in the sense that the Secretary is ‘not to refuse’ to list goods unless satisfied of certain matters (s 26(1)(c) to (n)). This distinction alone does not establish the extent to which the provision of data for Registered Goods is more onerous and extensive in practice. For example, it is a prerequisite for Listed Goods that any requirements imposed by the Secretary under s 31 in relation to the goods are complied with (s 26(1)(b)). This may include requirements imposed by the Secretary to provide information or documents relating to, among other things, safety, quality and efficacy (ss 31(2)(f) and (h) of the TG Act; regs 16AA(a) and (b) of the TG Regulations).

Decision

Reasons for decision

BENNETT J
In the circumstances, I will hear further from the parties on the application for the stay and the undertaking. CONCLUSION An inclusion in the ARTG, including an export only listing as Listed Goods, is an inclusion in the ARTG for the purposes of s 70 of the Act. Where that inclusion precedes registration that permits marketing in Australia and no “pre-TGA marketing approval” was given, it is the “first inclusion in the ARTG” and the “first regulatory approval date” for the purposes of calculating the period of extension pursuant to s 77 of the Act. The application, being an appeal against the decision of the Commissioner, should be dismissed. The applicants should pay the costs of the Commissioner. Spirit informed the Court on 20 December 2005 that, as a condition of its joinder to this proceeding, it would not seek costs. I will hear from the parties as to Pfizer’s application for the stay, the costs of that application and any undertaking as to damages.

Ratio Decidendi

Legal Principle Established

Established by: BENNETT J